HCA Holdings Gets a Buy Rating from Robert W. Baird

By Jason Carr

Robert W. Baird analyst Whit Mayo reiterated a Buy rating on HCA Holdings (NYSE: HCA) yesterday and set a price target of $104. The company’s shares closed yesterday at $86.97.

According to TipRanks.com, Mayo is a 3-star analyst with an average return of 2.1% and a 51.8% success rate. Mayo covers the Services sector, focusing on stocks such as Encompass Health Corporation, Fresenius Medical Care Corp, and Quest Diagnostics Inc.

Currently, the analyst consensus on HCA Holdings is Moderate Buy and the average price target is $94.86, representing a 9.1% upside.

In a report issued on January 10, Argus Research also maintained a Buy rating on the stock with a $97 price target.

Based on HCA Holdings’ latest earnings report for the quarter ending September 30, the company posted quarterly revenue of $10.7 billion and quarterly net profit of $426 million. In comparison, last year the company earned revenue of $10.64 billion and had a net profit of $920 million.

Based on the recent corporate insider activity of 106 insiders, corporate insider sentiment is negative on the stock. Most recently, in December 2017, Victor Campbell, the SVP of HCA bought 5,600 shares for a total of $33,488.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

HCA Healthcare, Inc. is a health care services company, which engages in operating hospitals, freestanding surgery centers and emergency rooms, and urgent care centers. It offers a full range of services to accommodate such medical specialties as internal medicine, general surgery, cardiology, oncology, neurosurgery, orthopedics and obstetrics, as well as diagnostic and emergency services. The company was founded on November 22, 2010 and is headquartered in Nashville, TN.